Navigation Links
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
Date:3/10/2008

GENEVA, Switzerland, March 10 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare type of melanoma (skin cancer) that is difficult to treat.

In comparative pre-clinical studies, ANAVEX 7-1037 reduced tumor growth by 69% with minimal side effects. Significantly, Dacarbazine, a currently available chemotherapy drug used to treat melanoma and other types of cancer, was found to be completely inactive in the same tests. ANAVEX 7-1037 is the company's lead drug candidate for the treatment of a number of cancers, including that of the breast, colon, prostate and melanoma. It exhibits a high safety profile and disease-modifying potential.

"These results further confirm the potent, anti-cancer activity and chemotherapeutic potential of ANAVEX 7-1037, even in cancers that are difficult to treat," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "We remain committed to developing first-class, cancer-fighting therapeutics based on our SIGMACEPTOR(TM) Discovery Platform, which utilizes a new class of receptor molecules known as sigma ligands to influence the origin or development of a disease."

ANAVEX 7-1037 More Effective in Pre-Clinical Studies

During pre-clinical studies, ANAVEX 7-1037 was administered directly into the abdominal cavity of immune-deficient mice at four different dose levels (100, 70, 40 and 10mg/kg). The mice had been inoculated subcutaneously with cancerous human cells on a "five days on, two days off" schedule. ANAVEX 7-1037 was administered beginning when tumors in advanced-stage subcutaneous mice models reached approximately 250 cubic millimeters in siz
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Anavex strengthens Board of Directors
2. Anavex advances drug candidate for treatment of Alzheimers disease
3. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. Heavier hydrogen on the atomic scale reduces friction
6. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Landfill mining reduces environmental impact of growing waste
9. Landfill mining reduces environmental impact of growing waste
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Assembly technique for tiny wires may eventually help detect cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... 2014   Sigma-Aldrich Corporation (Nasdaq: ... into a new gene editing partnership with the ... Under the partnership, Sigma-Aldrich will provide the Vector ... and dedicated gene editing bioinformaticians. The ... at the U-M Medical School. One initiative already ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... SAN DIEGO, April 28, 2011 Optimer Pharmaceuticals, Inc. ... from the DIFICID™ Phase 3 trials will be presented ... Place, Chicago, ILMay 7-10, 2011 Poster Presentation Information: Title: ... Treatment of Clostridium difficile Infection: ...
... Calif., April 28, 2011 AquaStar Holdings, Inc. (Pink ... that the United States Patent and Trademark Office has ... Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay ... Capillary Sensor" details research completed at the State University ...
... April 28, 2011 The Center for Business Intelligence (CBI), ... partnership with the Children,s Rare Disease Network and The Global ... coming up July 12 - 13, 2011 at the Doubletree ... about rare diseases. They affect few people individually, but there ...
Cached Biology Technology:Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 2Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings 3AquaStar Holdings, Inc.'s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... movements during the Vietnam war could help ecologists monitor ... in the British Ecological Society's Journal of Applied Ecology. ... recorded the vibrations from the footfalls of elephants and ... a geophone buried near a path leading to a ...
... discovered that a protein prolonging life in mice works by ... several species. In mice, the researchers discovered, it acts as ... , Therapies based on this hormone could prove to be ... Dr. Makoto Kuro-o, assistant professor of pathology and senior author ...
... Coyotes tend to avoid human contact. But recently, coyotes ... States, including southeastern New York state, attacking neighborhood pets ... "This kind of aggressive behavior is usually the last ... as small children that are perceived by the coyotes ...
Cached Biology News:Vietnam war technology could aid elephant conservation 2Scientists find that protein controls aging by controlling insulin 2Why are coyotes getting more aggressive? 2
...
TXNL2 Antibody...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: